Somatostatin inhibits both in-vitro and in-vivo carcinoembryonic antigen secretion by human colon cancer.

This study investigated the effect of SMS 201.995 on CEA secretion of human colon cancer cell lines in vitro and as xenografts in nude mice. Using the two cell lines which secreted significant amounts of CEA in the media, there was a 40% and 54% decrease in CEA level at 2e-10M and 2e-9M concentrations of SMS 201.995, respectively, after five days of incubation for LIM 2412 cell line (P < 0.05, both). There was a 13% decrease in CEA at 2e-9M concentration of SMS with the LoVo cell line (P > 0.05). In vivo, there was a direct correlation between the mean volume of the LIM 2412 xenografts and serum CEA level (r = 0.92). When the growth of xenografts was inhibited by SMS, there was a corresponding drop in serum CEA. On the other hand, when tumor sizes remained unchanged, whether after a short duration of SMS treatment or with the oral route, serum CEA was unaffected. Thus, CEA concentration reflected cell number in vitro and tumor size in vivo as a response to treatment with SMS 201.995. The CEA level may therefore be a useful marker during somatostatin treatment to monitor tumor response.

Laboratory and animal model evaluation of the Cryotech LCS 2000 in hepatic cryotherapy.

Hepatic cryotherapy is increasingly used in the treatment of patients with multiple hepatic metastases, particularly from colorectal cancer. The Cryotech LCS 2000 system, with insulated shaft-circulated liquid nitrogen probes, was designed for this purpose and was evaluated on the bench and in an animal model. The 9-mm probe was considerably more effective than the 5-mm probe when judged on time to create an iceball of a given diameter. The use of thawing gas reduced the time until the probe could be removed from 25 to 5 min but heated gas only produced a further reduction of 2 min. In the animal model, significant reduction in treatment times occurred with vascular inflow occlusion. The zone of necrosis as a percentage of the original iceball diameter was significantly higher following a twin freeze/thaw cycle. The relationship of the edge of the iceball to the eventual zone of hepatic necrosis was studied using different unabsorbable markers. India ink and sutures proved unreliable but a Teflon cannula was more successful and the margin was only of the order of 2 mm. The discrepancy between this observation and the percentage of the original iceball diameter which apparently becomes necrotic (64 and 82%) for single- and double-freeze lesions, respectively, suggests that the cryolesion undergoes shrinkage within 1 month and that the diameter of necrosis underestimates the true zone of destruction.

SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer.

The effect of a long-acting somatostatin analogue SMS 201.995 (SMS; Sandoz) on basal and gastrin-stimulated growth of 4 human colon cancer lines was studied in vitro and in vivo. Proliferation assay was done with overnight [75Se]selenomethionine uptake after 5 days of incubation. Gastrin concentrations used were 5e-10 M and 1e-7 M. SMS concentrations were from 2e-12 M to 2e-7 M. Cell lines LIM 1215, LIM 2405, and LIM 2412 were inhibited dose-dependently in both basal and gastrin-stimulated groups. LIM 1863 was slightly stimulated. Based on in vivo growth characteristics, LIM 2412 and LIM 2405 were selected for xenograft study. The dose of 50 micrograms/kg/day was arrived at after a preliminary experiment showed it to be safe and effective. The LIM 2412 xenografts in the SMS-treated animals were 473.3 +/- 99.9 (SD) versus 838.1 +/- 111.3 mm3 in control (P less than 0.05) after 20 days. The LIM 2405 tumors were also significantly inhibited (81.2 +/- 30.0 versus 245.7 +/- 48.3 mm3, P less than 0.01). The effect of SMS appeared to be reversible. Oral SMS at 200 micrograms/kg/day was not absorbed. This study suggests that SMS may have direct antitumor effects in human colon cancer.